Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthcare Press Micronesia.
Press releases published on April 30, 2025
DEBRICHEM® Wins 2025 IIWCG Achievement Award for Innovation in Wound Care
GlobeNewswire
·
April 30, 2025
AMSTERDAM, April 30, 2025 (GLOBE NEWSWIRE) -- DEBRICHEM®, the flagship product of DEBx Medical has been awarded the IIWCG Achievement Award 2025 for Innovation in Wound Care at the 16th Abu Dhabi Wound Care Conference. Media Snippet. Presented during the …
DEBRICHEM® se voit décerner le prix 2025 IIWCG Achievement Award récompensant l’innovation dans le domaine du soin des plaies
GlobeNewswire
·
April 30, 2025
AMSTERDAM, 30 avr. 2025 (GLOBE NEWSWIRE) -- DEBRICHEM®, le produit phare de DEBx Medical, a obtenu le prix IIWCG Achievement Award 2025 récompensant l’innovation dans le domaine du soin des plaies lors de la 16e conférence d’Abu Dhabi sur le soin des …
DEBRICHEM® זכה בפרס ההישגיות של IIWCG לשנת 2025 עבור חדשנות בטיפול בפצעים
GlobeNewswire
·
April 30, 2025
אמסטרדם, April 30, 2025 (GLOBE NEWSWIRE) -- DEBRICHEM®, מוצר הדגל של DEBx Medical, זכה בפרס ההישגיות של IIWCG לשנת 2025 עבור חדשנות בטיפול בפצעים ב-16th Abu Dhabi Wound Care Conference. קטע מדיה הכרה זו, שהוענקה במהלך טקס הפתיחה של ADNEC, מטעם הקבוצה הבין …
Best Testosterone Booster Supplements For Men: New Report Reveals Which Products Actually Work.
GlobeNewswire
·
April 30, 2025
New York, April 30, 2025 (GLOBE NEWSWIRE) -- WhatBest, a trusted resource for product research and rankings, has officially announced its list of the top 5 best testosterone boosters for men, showcasing five high-performing supplements identified through …
RetinAI and FVS Announce CE-MDR Certification for Co-developed AI-based Diabetic Retinopathy Screening Algorithm, LuxIA®
GlobeNewswire
·
April 30, 2025
BERN, Switzerland and MADRID, April 30, 2025 (GLOBE NEWSWIRE) -- RetinAI US Inc. (RetinAI) and Fundación Ver Salud (FVS) are pleased to jointly announce that LuxIA®, their co-developed innovative AI algorithm for Diabetic Retinopathy (DR) screening, has …
Nanobiotix Announces Presentation of Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer Followed by a Conference Call
GlobeNewswire
·
April 30, 2025
Full results from the completed dose escalation part and dose expansion parts of a Phase 1 study evaluating JNJ-1900 (NBTXR3) after induction chemotherapy for patients with locally advanced or borderline resectable pancreatic cancer to be presented by …
Nanobiotix présente les résultats complets de l’étude de Phase 1 évaluant JNJ-1900 (NBTXR3) dans le cancer du pancréas et organise une conférence téléphonique et webcast
GlobeNewswire
·
April 30, 2025
L’ensemble des résultats des parties d’escalade et d’expansion de dose de l’étude de Phase 1 évaluant JNJ-1900 (NBTXR3) après chimiothérapie d’induction chez des patients atteints d’un cancer du pancréas localement avancé ou à la limite de la résécabilité …
Présentation des résultats d’une collaboration de recherche en Immuno-Oncologie avec le Centre Léon Bérard - Au congrès annuel de l’AACR 2025
GlobeNewswire
·
April 30, 2025
Présentation des résultats d’une collaboration de recherche en Immuno-Oncologie avec le Centre Léon Bérard Au congrès annuel de l’AACR 2025 Une nouvelle signature d’expression génique pour prédire la réponse clinique aux points de contrôle immunitaires …
Nicox Provides Full Year 2024 Financial Results
GlobeNewswire
·
April 30, 2025
Nicox SA revenue of €7.9 million for full year 2024 Exceptional income of €13.7 million following the transfer of VYZULTA’s future revenue stream to Soleus Capital Nicox SA cash of €10.5 million on 31 December 2024 and the Company estimates it is …
Augustine Therapeutics builds its Management Team with Virginie Cartage joining as CFO and Dr. Andy Hu as CBO
GlobeNewswire
·
April 30, 2025
Augustine Therapeutics builds its Management Team with Virginie Cartage joining as CFO and Dr. Andy Hu as CBO New recruits expand senior team capabilities as the business progresses its lead HDAC6 inhibitor program, AGT-100216, into the clinic for the …
Addex Enters Option Agreement with Sinntaxis for an Exclusive License to Intellectual Property Covering the Use of mGlu5 Inhibitors in Brain Injury Recovery
GlobeNewswire
·
April 30, 2025
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 30, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for …
Sandoz reports Q1 2025 net sales in line with company expectations; full-year guidance confirmed
GlobeNewswire
·
April 30, 2025
Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Q1 2025 net sales of USD 2,480 million up by 3% in constant currencies (cc); stable in USD up by 5%[1] at a comparable growth rate (CGR), when adjusted for impact of …
Basel Medical Group Completes Acquisition of Bethesda Medical to Strengthen Healthcare Ecosystem in Singapore and Southeast Asia
GlobeNewswire
·
April 30, 2025
Singapore , April 30, 2025 (GLOBE NEWSWIRE) -- Basel Medical Group Ltd (Nasdaq: BMGL), today announced the closing of the acquisition of Bethesda Medical Pte. Ltd., a leading Singapore-based healthcare provider specializing in diagnostic imaging and …
Rakovina Strengthens Board with Appointments of Yevgeniy Meshcherekov and David Kideckel
GlobeNewswire
·
April 30, 2025
VANCOUVER, British Columbia, April 29, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing innovative cancer therapies through artificial intelligence (AI)-powered drug discovery, is pleased to …